Shumilov E, Wurm-Kuczera R, Kauer J, Wang M, Mazzeo P, Boyadzhiev H, Gebauer N, Holtick U, Hölscher A, Teichert M, Nierychlewska PM, Kimmich C, Berning P, Melchardt T, Zeremski V, Wirths C, Nakov P, Schultze-Florey C, Velazquez GF, Lesan V, Krämer I, Kaiser F, Vehling-Kaiser U, Ossami-Saidy A, Huber H, Behringer A, Bentz M, Scholz JK, Gödel P, Schnetzke U, Vucinic V, Shorb E, Ghandili S, Kerkhoff A, Scheich S, Aydin S, Mayer K, Bacher U, Wille K, Glass B, Oellerich T, Ayuk F, Heidel F, Thurner L, Lutz M, Hänel M, Scholz CW, Tometten M, Pott C, Dreger P, Mougiakakos D, Dietrich S, Derenzini E, Chapuy B, Tresckow B von, Pabst T, Müller F, Lenz G. Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma. haematol [Internet]. 2020Sep.10 [cited 2026Apr.9];. Available from: https://haematologica.org/article/view/13432